Korea Investment Partners to finance Jlm-based Enlivex Therapeutics’s lead compound for the prevention of Graft Vs Host Disease (GVHD)

Sept 20, 2017 - Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, announced today the closing of an $8 million equity financing round at a valuation of approximately $50 Million pre-closing. Korea Investment Partners (KIP)…

Continue ReadingKorea Investment Partners to finance Jlm-based Enlivex Therapeutics’s lead compound for the prevention of Graft Vs Host Disease (GVHD)